drugset / Trial / NCT00289757

Long-Term Immune Persistence of GlaxoSmithKline Biologicals' Inactivated Hepatitis A Vaccine, Injected According to 0, 6-month Schedule

NCT00289757

Phase 4 Completed 78 enrolled GlaxoSmithKline
RandomizedParallel-groupOpen-labelPrevention

Summary

The aim of this study is to evaluate the long-term persistence of hepatitis A antibodies at 11, 12, 13, 14, 15, 16, 17, 18, 19 and 20 years after subjects received their first dose of a 2 dose vaccination schedule of hepatitis A vaccine.

Timeline

Start
2004-01-01
Primary completion
2013-03-01
Completion
2013-03-01

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Havrix Vaccine Other